 |
BioWorld-Insight-2002-12-09
Money Raised Year To Date
Analyst: Gilead/Triangle's HIV Drug, Facing GSK's, May Need More Trials
Almost as if to provide a metaphor for HIV treatment strategy - drug combination is the weapon of choice for fighting the infection - two major players said last week they plan to join forces in a $464 million merger whereby Gilead Sciences Inc. will acquire Triangle Pharmaceuticals Inc. (BioWorld Financial Watch)